Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence.

The uptake and activation of FXII from blood plasma was studied in small-diameter polyethylene tubing, surface-modified by end-point immobilization of heparin. Two preparations of heparin were used to modify the contact-activating properties of the plastic tubing: unfractionated, functionally active heparin and low-affinity heparin, lacking the specific antithrombin-binding sequence and virtually devoid of anticoagulant activity. The uptakes of FXII on the two heparin surfaces were similar. No activated FXII could be demonstrated on the unfractionated heparin surface, whereas on the low-affinity heparin surface nearly all FXII underwent spontaneous activation. The suppression of FXII activation on the unfractionated heparin surface was investigated by using plasma depleted of antithrombin, complement C1 esterase inhibitor, or both. The removal of antithrombin resulted in extensive activation of FXII, whereas the depletion of C1 esterase inhibitor had only a minor effect. Experiments with recalcified plasma showed rapid clot formation during exposure to the low-affinity heparin surface. After depletion of antithrombin, but not complement C1 esterase inhibitor, the recalcified plasma clotted in contact with the unfractionated heparin surface as well. We conclude that antithrombin and the antithrombin-binding sequence in the surface-immobilized heparin are essential for the prevention of surface activation of FXII and triggering of the intrinsic coagulation system.

[1]  G. Elgue,et al.  Effect of surface-immobilized heparin on the activation of adsorbed factor XII. , 2008, Artificial organs.

[2]  G. Elgue,et al.  The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure. , 1994, Thrombosis research.

[3]  G. Elgue,et al.  On the Mechanism of Coagulation Inhibition on Surfaces with End Point Immobilized Heparin , 1993, Thrombosis and Haemostasis.

[4]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[5]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[6]  G. Elgue,et al.  Binding of antithrombin to immobilized heparin under varying flow conditions. , 1991, Artificial organs.

[7]  V. Videm,et al.  Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. , 1991, The Journal of thoracic and cardiovascular surgery.

[8]  E. Hack,et al.  Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. , 1991, The Journal of allergy and clinical immunology.

[9]  B. Liedberg,et al.  Infrared characterization of complex sandwich structures: Heparin immobilized on polyethylene surfaces , 1991 .

[10]  G. Elgue,et al.  The Use of a Commercial ELISA for Assay of Thrombin-Antithrombin Complexes in Purified Systems , 1990, Thrombosis and Haemostasis.

[11]  C. Geisen,et al.  Heparin free long-term extracorporeal circulation using bioactive surfaces. , 1989, ASAIO transactions.

[12]  O. Larm,et al.  Antithrombin III Binding to Surface Immobilized Heparin and Its Relation to F Xa Inhibition , 1987, Thrombosis and Haemostasis.

[13]  A. Schmaier,et al.  Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. , 1987, Archives of biochemistry and biophysics.

[14]  R. Colman,et al.  The regulation of human factor XIIa by plasma proteinase inhibitors. , 1985, The Journal of biological chemistry.

[15]  R. Colman,et al.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. , 1984, The Journal of clinical investigation.

[16]  J. Marcum,et al.  Anticoagulantly active heparin-like molecules from vascular tissue. , 1984, Biochemistry.

[17]  J. Finlayson,et al.  Kinetics of activation and autoactivation of human factor XII. , 1984, Biochemistry.

[18]  J J Pisano,et al.  Hageman factor fragment inhibitor in corn seeds: purification and characterization. , 1980, Thrombosis research.

[19]  J. Griffin,et al.  Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma , 1978, The Journal of experimental medicine.

[20]  R. Rosenberg,et al.  Inhibition of activated factor XII by antithrombin-heparin cofactor. , 1976, The Journal of biological chemistry.

[21]  H. Hansson,et al.  Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. , 1992, Scandinavian journal of thoracic and cardiovascular surgery.

[22]  W. Rees,et al.  Studies on synthetic peptide substrates for F XII enzymes. , 1986, Advances in experimental medicine and biology.

[23]  R. Larsson,et al.  A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.

[24]  B. Lämmle,et al.  Amidolytic activity in normal human plasma assessed with chromogenic substrates. , 1979, Thrombosis research.